Accessibility Statement Skip Navigation
  • Why PRWeb
  • How It Works
  • Who Uses It
  • Pricing
  • Login
  • GDPR
  • Create a Free Account
Return to PRWeb homepage
  • News
  • Resources
  • Contact
When typing in this field, a list of search results will appear and be automatically updated as you type.

Searching for your content...

No results found. Please change your search terms and try again.
  • News in Focus
      • Browse News Releases

      • All News Releases
      • Multimedia Gallery

      • All Multimedia
      • All Photos
      • All Videos
  • Business & Money
      • Auto & Transportation

      • Aerospace, Defense
      • Air Freight
      • Airlines & Aviation
      • Automotive
      • Maritime & Shipbuilding
      • Railroads and Intermodal Transportation
      • Supply Chain/Logistics
      • Transportation, Trucking & Railroad
      • Travel
      • Trucking and Road Transportation
      • View All Auto & Transportation

      • Business Technology

      • Blockchain
      • Broadcast Tech
      • Computer & Electronics
      • Computer Hardware
      • Computer Software
      • Data Analytics
      • Electronic Commerce
      • Electronic Components
      • Electronic Design Automation
      • Financial Technology
      • High Tech Security
      • Internet Technology
      • Nanotechnology
      • Networks
      • Peripherals
      • Semiconductors
      • View All Business Technology

      • Entertain­ment & Media

      • Advertising
      • Art
      • Books
      • Entertainment
      • Film and Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • View All Entertain­ment & Media

      • Financial Services & Investing

      • Accounting News & Issues
      • Acquisitions, Mergers and Takeovers
      • Banking & Financial Services
      • Bankruptcy
      • Bond & Stock Ratings
      • Conference Call Announcements
      • Contracts
      • Cryptocurrency
      • Dividends
      • Earnings
      • Earnings Forecasts & Projections
      • Financing Agreements
      • Insurance
      • Investments Opinions
      • Joint Ventures
      • Mutual Funds
      • Private Placement
      • Real Estate
      • Restructuring & Recapitalization
      • Sales Reports
      • Shareholder Activism
      • Shareholder Meetings
      • Stock Offering
      • Stock Split
      • Venture Capital
      • View All Financial Services & Investing

      • General Business

      • Awards
      • Commercial Real Estate
      • Corporate Expansion
      • Earnings
      • Environmental, Social and Governance (ESG)
      • Human Resource & Workforce Management
      • Licensing
      • New Products & Services
      • Obituaries
      • Outsourcing Businesses
      • Overseas Real Estate (non-US)
      • Personnel Announcements
      • Real Estate Transactions
      • Residential Real Estate
      • Small Business Services
      • Socially Responsible Investing
      • Surveys, Polls and Research
      • Trade Show News
      • View All General Business

  • Science & Tech
      • Consumer Technology

      • Artificial Intelligence
      • Blockchain
      • Cloud Computing/Internet of Things
      • Computer Electronics
      • Computer Hardware
      • Computer Software
      • Consumer Electronics
      • Cryptocurrency
      • Data Analytics
      • Electronic Commerce
      • Electronic Gaming
      • Financial Technology
      • Mobile Entertainment
      • Multimedia & Internet
      • Peripherals
      • Social Media
      • STEM (Science, Tech, Engineering, Math)
      • Supply Chain/Logistics
      • Wireless Communications
      • View All Consumer Technology

      • Energy & Natural Resources

      • Alternative Energies
      • Chemical
      • Electrical Utilities
      • Gas
      • General Manufacturing
      • Mining
      • Mining & Metals
      • Oil & Energy
      • Oil and Gas Discoveries
      • Utilities
      • Water Utilities
      • View All Energy & Natural Resources

      • Environ­ment

      • Conservation & Recycling
      • Environmental Issues
      • Environmental Policy
      • Environmental Products & Services
      • Green Technology
      • Natural Disasters
      • View All Environ­ment

      • Heavy Industry & Manufacturing

      • Aerospace & Defense
      • Agriculture
      • Chemical
      • Construction & Building
      • General Manufacturing
      • HVAC (Heating, Ventilation and Air-Conditioning)
      • Machinery
      • Machine Tools, Metalworking and Metallurgy
      • Mining
      • Mining & Metals
      • Paper, Forest Products & Containers
      • Precious Metals
      • Textiles
      • Tobacco
      • View All Heavy Industry & Manufacturing

      • Telecomm­unications

      • Carriers and Services
      • Mobile Entertainment
      • Networks
      • Peripherals
      • Telecommunications Equipment
      • Telecommunications Industry
      • VoIP (Voice over Internet Protocol)
      • Wireless Communications
      • View All Telecomm­unications

  • Lifestyle & Health
      • Consumer Products & Retail

      • Animals & Pets
      • Beers, Wines and Spirits
      • Beverages
      • Bridal Services
      • Cannabis
      • Cosmetics and Personal Care
      • Fashion
      • Food & Beverages
      • Furniture and Furnishings
      • Home Improvement
      • Household, Consumer & Cosmetics
      • Household Products
      • Jewelry
      • Non-Alcoholic Beverages
      • Office Products
      • Organic Food
      • Product Recalls
      • Restaurants
      • Retail
      • Supermarkets
      • Toys
      • View All Consumer Products & Retail

      • Entertain­ment & Media

      • Advertising
      • Art
      • Books
      • Entertainment
      • Film and Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • View All Entertain­ment & Media

      • Health

      • Biometrics
      • Biotechnology
      • Clinical Trials & Medical Discoveries
      • Dentistry
      • FDA Approval
      • Fitness/Wellness
      • Health Care & Hospitals
      • Health Insurance
      • Infection Control
      • International Medical Approval
      • Medical Equipment
      • Medical Pharmaceuticals
      • Mental Health
      • Pharmaceuticals
      • Supplementary Medicine
      • View All Health

      • Sports

      • General Sports
      • Outdoors, Camping & Hiking
      • Sporting Events
      • Sports Equipment & Accessories
      • View All Sports

      • Travel

      • Amusement Parks and Tourist Attractions
      • Gambling & Casinos
      • Hotels and Resorts
      • Leisure & Tourism
      • Outdoors, Camping & Hiking
      • Passenger Aviation
      • Travel Industry
      • View All Travel

  • Policy & Public Interest
      • Policy & Public Interest

      • Advocacy Group Opinion
      • Animal Welfare
      • Congressional & Presidential Campaigns
      • Corporate Social Responsibility
      • Domestic Policy
      • Economic News, Trends, Analysis
      • Education
      • Environmental
      • European Government
      • FDA Approval
      • Federal and State Legislation
      • Federal Executive Branch & Agency
      • Foreign Policy & International Affairs
      • Homeland Security
      • Labor & Union
      • Legal Issues
      • Natural Disasters
      • Not For Profit
      • Patent Law
      • Public Safety
      • Trade Policy
      • U.S. State Policy
      • View All Policy & Public Interest

  • People & Culture
      • People & Culture

      • Aboriginal, First Nations & Native American
      • African American
      • Asian American
      • Children
      • Diversity, Equity & Inclusion
      • Hispanic
      • Lesbian, Gay & Bisexual
      • Men's Interest
      • People with Disabilities
      • Religion
      • Senior Citizens
      • Veterans
      • Women
      • View All People & Culture

  • Hamburger menu
  • Cision PRWeb provides efficient communication tools to continuously engage with target audiences across multiple online channels
  • Create a Free Account
    • ALL CONTACT INFO
    • Contact Us


      11AM ET Sunday – 8PM ET Friday

  • Send a Release
  • Sign up
  • Log in
  • Resources
  • RSS
  • GDPR
  • News in Focus
    • Browse All News
    • Multimedia Gallery
  • Business & Money
    • Auto & Transportation
    • Business Technology
    • Entertain­ment & Media
    • Financial Services & Investing
    • General Business
  • Science & Tech
    • Consumer Technology
    • Energy & Natural Resources
    • Environ­ment
    • Heavy Industry & Manufacturing
    • Telecomm­unications
  • Lifestyle & Health
    • Consumer Products & Retail
    • Entertain­ment & Media
    • Health
    • Sports
    • Travel
  • Policy & Public Interest
  • People & Culture
    • People & Culture
  • Send a Release
  • Sign up
  • Log in
  • Resources
  • RSS
  • GDPR
  • Send a Release
  • Sign up
  • Log in
  • Resources
  • RSS
  • GDPR
  • Send a Release
  • Sign up
  • Log in
  • Resources
  • RSS
  • GDPR

American Association of Poison Control Centers Issues Warning about Reemerging Synthetic Drugs
  • USA - English


News provided by

AAPCC

Apr 23, 2015, 12:50 ET

Share this article

Share toX

Share this article

Share toX

AAPCC Logo
AAPCC Logo

Alexandria, VA (PRWEB) April 23, 2015 -- The American Association of Poison Control Centers (AAPCC) and the experts at America’s 55 poison centers are warning the public about a group of dangerous new synthetic cannabinoids which have recently led to a dramatic spike in poison center exposure calls in the United States, according to Stephen T. Kaminski, JD, AAPCC executive director.

These synthetic drugs present a potentially fatal risk that is not well recognized by people consuming these products.

Post this

Poison centers across the country have been receiving increased levels of calls related to these substances. From Jan. 1, 2015, through April 22, 2015, poison centers have received 1,900 exposure calls from people seeking help for adverse reactions to these drugs; this is almost four times the rate of calls received in 2014. In New York, Governor Andrew Cuomo issued a health alert stating that New York emergency departments have reported seeing more than 160 patients in a nine day period. Alabama has seen 317 synthetic cannabinoid-related emergency department visits in an 18 day window as of April 20, 2015. Other states such as New Jersey, Mississippi, Texas, Florida and Arizona have also seen dramatic increases in reports, signaling this is a national problem.

Synthetic “marijuana” products, also known as THC homologs, are in reality very different from marijuana. Health effects from the drug can be life-threatening and can include:

  • Severe agitation and anxiety
  • Fast, racing heartbeat and higher blood pressure
  • Nausea and vomiting
  • Muscle spasms, seizures, and tremors
  • Intense hallucinations and psychotic episodes
  • Suicidal and other harmful thoughts and/or actions

Physicians can experience difficulty trying to determine the cause of severe medical problems seen in users of these substances when they present to emergency departments due to the wide variety of chemicals used to make synthetic cannabinoids. These drugs are imported into the United States and can be sprayed on plant material or combined in other ways and marketed under such names as “Spice,” “K2,” “Keisha Kole,” “Summit,” “AK-47” and many others.

The harmful effects from these products were first reported in the U.S. in 2009. Since then, the synthetic drugs have spread throughout the country due to ease of access. For example, people are able to purchase them at gas station convenience stores. The chemical formula of these substances changes from one week to the next to avoid regulations banning specific compound formulations. As a result, the same brand purchased at different times may produce vastly different effects.

“These synthetic drugs present a potentially fatal risk that is not well recognized by people consuming these products,” said AAPCC President Jay Schauben, PharmD, DABAT, FAACT. “The recent death of five people suspected of using this category of drugs underscores the urgency of controlling these drugs and educating the public of their dangers.”

The Centers for Disease Control and Prevention (CDC) and AAPCC have conducted public health surveillance using data stored in the National Poison Data System (NPDS) since 2000 to help identify and characterize emerging public health threats.

"We're greatly concerned by the rise in calls to poison centers regarding synthetic cannabinoids," said Dr. Amy Wolkin, chief of the CDC’s Health Studies Branch. "The perception that these drugs are harmless is dangerous. People and hospitals need to be aware of the potential harm they can do."

“Our research shows that people are playing Russian Roulette with their lives because only the chemist creating the synthetic cannabinoid really knows what is in it,” said Dr. Eric Wish, director of the Coordinating Center for the National Institute on Drug Abuse (NIDA) funded National Drug Early Warning System (NDEWS) located at the University of Maryland, College Park. “We have found very different metabolites in different sites across the country and even in the same site over time.”

Erin Artigiani, NDEWS co-investigator, added, “We are very excited about the new partnership between NDEWS and AAPCC and the unique opportunity it provides to work together to identify and discuss new synthetic drugs as they emerge.”

"One of the strengths of the poison center network is its ability to identify emerging public health threats virtually in real-time,” said Kaminski. "Poison centers are staffed with medical professionals who are available 24 hours a day, seven days a week, to answer questions about ‘K2,’ ‘Spice,’ or any other substances that could be harmful to your health. All calls are confidential."

For more information, the media may contact Brett Schuster, AAPCC associate manager, Public Relations and Member Services, at 703.894.1865 or schuster(at)aapcc(dot)org.

For information about NDEWS, please contact Erin Artigiani at 301-705-9794 or eartigia(at)umd(dot)edu.

AAPCC supports the nation’s 55 poison center members in their efforts to treat and prevent drug, consumer product, animal, environmental and food poisoning. Members staff the Poison Help hotline at 1-800-222-1222 that provides free, confidential, expert medical advice 24 hours a day, seven days a week, 365 days a year from toxicology specialists, including nurses, pharmacists, physicians, and poison information providers. In addition, AAPCC maintains the only poison information and surveillance database in the United States, providing real-time monitoring of unusual poisoning patterns, chemical exposures and other emerging public health hazards. AAPCC partners with federal agencies such as EPA, HRSA and the CDC, as well as private industry.

To learn more, visit http://www.aapcc.org, like us on Facebook, follow us on Twitter (@AAPCC), and read our blog at aapcc.wordpress.com.

To learn more about NDEWS, visit http://www.cesar.umd.edu/cesar/cesarfax/vol23/23-12.pdf and http://www.drugabuse.gov/news-events/news-releases/2014/07/nih-system-to-monitor-emerging-drug-trends.

People interested in joining the ongoing discussions about synthetic cannabinoids are welcome to join the NDEWS Network, a virtual community of more than 500 substance abuse experts, practitioners and concerned citizens working together to educate each other and the general public about substance abuse and its consequences.

Brett Schuster, AAPCC, http://www.aapcc.org, +1 (703) 894-1865, [email protected]

Modal title

Contact PRWeb

  • 11AM ET Sunday – 8PM ET Friday
  • Contact Us

About PRWeb

  • About PRWeb
  • Partners
  • Partnership Programs
  • Editorial Guidelines
  • Resources

Why PRWeb

  • Why PRWeb
  • How It Works
  • Who Uses It
  • Pricing

Accounts

  • Create a Free Account
  • Log in
  • Contact Us

Do not sell or share my personal information:

  • Submit via [email protected] 
  • Call Privacy toll-free: 877-297-8921

Contact Cision

Products

About

My Services
  • All News Releases
  • Online Member Center
  • ProfNet
Cision Distribution Helpline
888-776-0942
  • Legal
  • Site Map
  • RSS
  • Cookie Settings
Copyright © 2025 Cision US Inc.